CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Dr. Chari on Impact of CAR T Cells in Myeloma

November 16th 2018

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the impact of CAR T-cell therapy in myeloma.

CAR T-Cell Therapies Moving to Outpatient Setting

November 8th 2018

The high durable response rates seen with CAR T-cell therapies have helped fill a high unmet need for patients with relapsed/refractory diffuse large B-cell lymphoma, with questions remaining on the optimal way to use these agents following the FDA approval of 2 therapies in the past year.

Dr. Ghobadi on the Potential Development of CAR T Cells in Solid Tumors

November 8th 2018

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential development of chimeric antigen receptor (CAR) T cells in solid tumors.

Dr. Smith Discusses CAR T Cell Persistence in Myeloma

November 2nd 2018

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric antigen receptor (CAR) T cell persistence in patients with multiple myeloma.

The Impact of Precision Medicine in Oncology

October 30th 2018

Ryan Bookout, PharmD, president, Hematology/Oncology Pharmacy Association, clinical pharmacist, Moffitt Cancer Center, discusses the impact of recent advances and precision medicine in oncology.

Future Directions for CAR-T Therapy

October 29th 2018

Expanding the Role of CAR T in non-Hodgkin Lymphoma

October 29th 2018

CAR-T Post-Infusion Care, Financial Considerations, and Data Management

October 29th 2018

The Production of CAR T Cells for non-Hodgkin Lymphoma

October 29th 2018

The Workflow of CAR-T Administration

October 29th 2018

The Logistics of Building a CAR-T Program

October 29th 2018

Patient Selection for CAR-T Therapy in NHL

October 29th 2018

CAR-T Safety & Post-Treatment Plans

October 29th 2018

Variations Among CAR T Products for NHL

October 29th 2018

Clinical Trials of CAR T-Cell Therapy in NHL

October 29th 2018

Clinical Data Surrounding CAR T-Cell Therapy in NHL

October 29th 2018

CAR T-Cell Therapies for Relapsed/Refractory NHL

October 29th 2018

Unmet Needs in Treating Relapsed NHL

October 29th 2018

Traditional Therapies for High-Risk Lymphoma and Efficacy

October 29th 2018

Reach of CAR T-Cell Therapy Poised to Extend in Oncology

October 26th 2018

Armin Ghobadi, MD, discusses the evolution and expansion of CAR T-cell therapy in oncology and how to maximize its application across liquid and solid tumors.